Cited by 221Virus-based gene therapy researchRNA Interference and Gene DeliveryBarrier Structure and Function Studies

Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS

Open access
Chamberlin, Nancy L., Du, Bin, de Lacalle, Sonsoles, Saper, Clifford B.·1998·Brain Research

Abstract

We used a recombinant adeno-associated virus vector (AAV) to deliver a foreign gene, green fluorescent protein (GFP), into mature neurons in adult rat CNS in vivo. Microinjections of AAV as small as 50 nl transduced hundreds of neurons at the injection site. There was virtually no retrograde transport as fewer than one neuron per brain was found distant from the injection site that exhibited GFP immunoreactivity. The gene product, GFP, filled the entire neuronal cytoplasmic compartment; GFP immunoreactivity was robust in cell bodies, axons, and nerve terminals. There was no tissue damage at the injection sites or pathogenicity indicated by changes in astrocytic or microglial markers. There was no inflammatory response as judged by leukocytic invasion. Gene expression in transduced cells was robust and apparently permanent: there was no evidence of phenotypic reversion up to 12 weeks following infection. AAV is an excellent vector for introducing foreign genes into mature CNS neurons. Not only might it be an ideal vehicle for gene therapy, but also the GFP-containing AAV presents a new strategy for tracing long axonal pathways in the CNS, which is difficult with current tracers (PHAL, biotinylated dextrans).

Integrity signals

Registry

Crossref · 10.1016/s0006-8993(98)00169-3

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Compared to conventional tracers which often have mixed anterograde and retrograde transport, retrograde labelling with AAV (except for certain serotypes) is generally negligible.

    “Second, compared to conventional tracers which often have mixed anterograde and retrograde transport, retrograde labelling with AAV (except for certain serotypes) is generally negligible.”

    From A mesoscale connectome of the mouse brain (2014) · cites this paper as [19]

  • AAV mediates robust fluorescent labelling of the soma and processes of infected neurons, which can be coupled with direct imaging methods for high-throughput production without additional histochemical staining steps.

    “First, AAV mediates robust fluorescent labelling of the soma and processes of infected neurons, which can be coupled with direct imaging methods for high-throughput production without additional histochemical staining steps.”

    From A mesoscale connectome of the mouse brain (2014) · cites this paper as [19]

  • AAV allows flexible molecular strategies to introduce various transgenes and to label specific neuronal populations by combining cell-type-selective Cre driver mice with AAV vectors harbouring a Cre-dependent expression cassette.

    “Finally, perhaps the greatest advantage of using AAV over conventional tracers is the flexible molecular strategies that can be used to introduce various transgenes and to label specific neuronal populations by combining cell-type-selective Cre driver mice with AAV vectors harbouring a Cre-dependent expression cassette.”

    From A mesoscale connectome of the mouse brain (2014) · cites this paper as [19]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chamberlin, N. L., Du, B., de Lacalle, S., & Saper, C. B.
Affiliations
Beth Israel Deaconess Medical Center (US)
Corresponding author
Chamberlin, Nancy L.
Venue
Brain Research
Publisher
Elsevier BV
Published
1998-05
Volume
793
Issue
1-2
Pages
169-175
ISSN
0006-8993 (ISSN-L)
OpenAlex
W2073539399
Cited by
221
References
14
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 9 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 12 · 2014: 8 · 2013: 16 · 2012: 9
FWCI
2.87
Type
journal article
Language
en
Open access
Locations
  • Brain Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • University of Florida
  • National Institutes of Health (5r01ns022835-11)
  • U.S. Public Health Service
  • National Institute on Aging (AG21856, R01AG019597, R29AG012401)
  • National Institute of Neurological Disorders and Stroke (NS 33987, R01NS033987, NS-22835)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
recombinant adeno-associated virus vectors, green fluorescent protein, axonal transport, retrograde transport, CNS gene therapy, microinjection
MeSH terms
Dependovirus, Animals, Axonal Transport, Brain, Cell Line, Genetic Vectors, Humans, Luminescent Proteins, Male, Neural Pathways, Recombination, Genetic, Gene Expression, Rats, Sprague-Dawley, Genes, Reporter, Transgenes, Green Fluorescent Proteins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review